In a Law360 article, health care partner and practice co-chair Tim McCrystal discussed the most influential 2025 midyear health care deals.
Tim cites Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies that includes the drug Caplyta, which is approved for the treatment of schizophrenia. Tim notes the deal reflects an expansion of J&J’s portfolio of neurology related drugs and the need for additional biopharmaceutical products and health care services in the neuro disease sector.
The article mentions the Walgreens Boots Alliance (WBA) $23.7 billion take-private transactions with Sycamore Partners as one of the top half-year health care deals and notes that Ropes & Gray is serving as health care regulatory advisor to WBA.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.